Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Free Dating
Ñompany Maksim-LLC. Ýëåêòðîïðèâîäû. Made and sell.
Popular Articles

Quality Data Made Accessible To Clinical Teams
NHS clinical teams will have access to data showing their performance against a set of more than 200 indicators of high quality care in the NHS in one place. It is the next phase in the drive to help NHS professionals improve the quality of care they deliver to patients, and will also support providers and commissioners of NHS services.
new payday loan lenders
Buy zoloft and forget about depression.
Molecular Insight Pharmaceuticals, Inc. Receives European Medicines Agency Approval To Proceed With Phase 3 Development Of OnaltaTM
Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced that the European Medicines Agency (EMEA) has approved its Phase 3 protocol for Onalta (Yttrium-90 edotreotide). Onalta is the Company"s lead radiotherapeutic product candidate under development for the treatment of metastatic carcinoid and pancreatic neuroendocrine tumors in patients whose symptoms are not controlled by conventional therapy. The compound has shown the potential to selectively deliver lethal radiation to cancer cells. The proposed Phase 3 trial will confirm that administration of Onalta results in stabilization, regression or complete remission of the carcinoid tumor, and improves carcinoid-related symptoms when compared to a high-dose regimen of the current standard therapy for this disease, Sandostatin®. With EMEA"s approval of its proposed Phase 3 protocol in hand, Molecular Insight can proceed with the final clinical trial that will position Onalta for marketing authorization in the EU.
News of the day
Pitt Study Redefines Binge Drinking For Children And Adolescents
The criteria used to assess blood alcohol concentrations (BACs) and binge drinking behaviors in children and adolescents should be based on pediatric rather than adult physiology, according to a new University of Pittsburgh study in the June issue of Pediatrics.
Health Insurance

Cylene To Announce New Data On Its First-in-Class Oral CK2 Inhibitor Against Cancer At BIO Conference

Cylene Pharmaceuticals, Inc., announced that it will present major advances in the development of their first-in-class, CK2 inhibitor CX-4945 at the 2009 BIO International Convention on Wednesday, May 20th at 4:40 pm. William G. Rice, Ph.D., Cylene"s president and CEO, will discuss the mechanism, antitumor properties and tumor selectivity of CX-4945, the Company"s oral protein kinase inhibitor currently in Phase I clinical trials. This proprietary compound has demonstrated promise as a potent and selective oral inhibitor of protein kinase CK2, a previously unexploited molecular target with well documented roles in many cancers, indicating broad therapeutic potential. Cylene"s Serine/Threonine Kinase Inhibitor program has also delivered orally active pan-PIM inhibitors of the PIM-1,2,3 kinases, still in pre-clinical development. Cylene Pharmaceuticals, Inc. is a Phase II-stage, small-molecule Oncology Company designing promising therapeutic agents with its two proprietary product discovery platforms, using novel chemistry and biology capabilities. The company was co-founded by Daniel Von Hoff, MD, one of the world"s leading oncology clinical investigators. In addition to the CK2 inhibitor CX-4945, Cylene"s Nucleolus Targeting Technology has generated Quarfloxin (CX-3543), a small molecule agent that is in Phase II development for the treatment of carcinoid/neuroendocrine tumors (C/NET). Quarfloxin disrupts an essential protein: DNA complex in cancer cells, thereby knocking out a critical of support for tumor cells and selectively causing cancer cell death. Quarfloxin is safe and well-tolerated and has completed two separate Phase I trials on different dosing schedules, during which biological activity was observed in several C/NET patients Cylene Pharmaceuticals, Inc

Team amazing race commented:

Good conference information. I appreciate the writer for the efforts to make this article so informative for the people

17.05.2012


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009